GSK Pharma Seeks Shareholder Nod for New CFO; Remuneration Package Detailed

GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) is seeking shareholder approval to appoint Mr. Ronojit Biswas as its Whole-time Director and Chief Financial Officer, effective April 1, 2026. The proposed annual basic salary stands at ₹1.92 crore, with an additional sign-on bonus of ₹20 lakh.

Shareholders will vote on ordinary resolutions concerning his appointment and remuneration during a postal ballot period from March 9 to April 8, 2026. The results of the vote are expected on or before April 10, 2026.

Reader Takeaway: Experienced finance veteran joins; shareholder nod & profit-linked pay adjustments are key.

What just happened

GSK Pharma has initiated a postal ballot process to seek shareholder consent for appointing Mr. Ronojit Biswas as an Additional Director and as Whole-time Director & Chief Financial Officer (CFO).

This strategic leadership change is slated to be effective from April 1, 2026, with Mr. Biswas appointed for a tenure of three years, concluding on March 31, 2029.

The proposed remuneration package includes a maximum basic salary of ₹16,00,000 per month (₹1.92 crore annually) and a performance bonus of up to 100% of his basic salary. A sign-on bonus of ₹20,00,000 is also proposed.

Why this matters

The appointment of a Chief Financial Officer is critical for steering a company's financial strategy, ensuring robust governance, and managing investor relations.

Mr. Biswas's extensive experience within the GSK group, spanning multiple geographies, suggests a focus on bringing continuity and seasoned financial leadership to GSK Pharma India.

The backstory

Ronojit Biswas is a seasoned finance executive with over 25 years of experience within the global GSK ecosystem, having started his career with the company in India in 1999.

His international exposure includes senior finance roles in India, Vietnam, Singapore, Brazil, and the United Kingdom, encompassing responsibilities such as Senior Finance Director for Global Product Strategy and CFO for GSK's businesses in Brazil and Vietnam.

This appointment follows the planned transition of current CFO Juby Chandy, who will step down on March 11, 2026, to lead the Asia-Pacific finance function for the wider GSK group, signaling a structured succession plan.

Globally, the GSK group has faced significant past regulatory scrutiny, including a substantial $3 billion settlement in 2012 for fraud and marketing practices, underscoring the importance of strong compliance and governance.

What changes now

Shareholders will have a direct say in approving the appointment of Mr. Biswas and his remuneration package.

His tenure as CFO will be key to guiding GSK Pharma India's financial planning, performance management, and compliance efforts.

The successful approval will confirm experienced leadership continuity in the finance function, vital for the company's strategic growth initiatives.

Risks to watch

The sign-on bonus of ₹20 lakh is recoverable by the company if Mr. Biswas leaves within one year of his joining date.

Remuneration payable to the Whole-time Director will be adjusted according to the Companies Act, 2013, if the company has no profits or inadequate profits during his tenure.

Peer comparison

CFOs in the Indian Pharmaceuticals & Healthcare sector typically earn between ₹75 lakh and ₹1.8 crore annually.

The average CFO salary in India ranges from ₹1 crore to ₹3 crore per year, varying by company size and industry.

GSK Pharma's proposed basic salary of ₹1.92 crore annually, alongside a performance bonus and sign-on bonus, places it at the higher end of industry benchmarks for large, established pharmaceutical companies in India.

Context metrics (time-bound)

• E-voting Period: March 9, 2026 (9:00 AM IST) to April 8, 2026 (5:00 PM IST).
• Appointment Effective Date: April 1, 2026.
• Results Announcement: On or before April 10, 2026.

What to track next

Monitor the outcome of the postal ballot and the official announcement of results by April 10, 2026.

Observe the smooth transition of financial leadership as Mr. Biswas assumes his role from April 1, 2026.

Keep an eye on how the new CFO's financial strategy aligns with GSK Pharma India's growth objectives and market dynamics.